Drugs / ABO1108
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07285265 | May → Nov 2025 overdue | varicella zoster infection | Suzhou Abogen Biosciences Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07285278 | Nov 2025 → Mar 2026 overdue | varicella zoster infection | Suzhou Abogen Biosciences Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABO1108 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07285265 ↗ |
| Modality | Messenger RNA (mRNA) | “Herpes Zoster mRNA Vaccine” NCT07285265 ↗ |